Header Logo

Connection

MALCOLM BRENNER to Leukemia

Back to Details
This is a "connection" page, showing publications MALCOLM BRENNER has written about Leukemia.
MALCOLM BRENNER
Connection Strength
1.195
Leukemia
  1. Vaccine therapies for pediatric malignancies. Cancer J. 2005 Jul-Aug; 11(4):331-9.
    View in: PubMed
    Score: 0.135
  2. Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208.
    View in: PubMed
    Score: 0.115
  3. Cure of leukemia. Semin Hematol. 1999 Oct; 36(4 Suppl 7):73-83.
    View in: PubMed
    Score: 0.091
  4. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clin Cancer Res. 2018 12 15; 24(24):6185-6194.
    View in: PubMed
    Score: 0.084
  5. Hematological malignancies. FASEB J. 1997 Jul; 11(8):640-8.
    View in: PubMed
    Score: 0.078
  6. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25.
    View in: PubMed
    Score: 0.062
  7. Immunotherapy of leukemia. Leukemia. 1992; 6 Suppl 1:76-9.
    View in: PubMed
    Score: 0.053
  8. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83.
    View in: PubMed
    Score: 0.052
  9. Graft versus leukaemia effects after marrow transplantation in man. Baillieres Clin Haematol. 1991 Jul; 4(3):727-49.
    View in: PubMed
    Score: 0.051
  10. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011 Mar 24; 117(12):3353-62.
    View in: PubMed
    Score: 0.050
  11. Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. Pediatr Blood Cancer. 2011 Jan; 56(1):143-51.
    View in: PubMed
    Score: 0.050
  12. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70.
    View in: PubMed
    Score: 0.047
  13. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1272-81.
    View in: PubMed
    Score: 0.047
  14. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood. 1989 Apr; 73(5):1351-8.
    View in: PubMed
    Score: 0.044
  15. Bone marrow transplantation in acute or chronic leukaemia. Acta Haematol. 1987; 78 Suppl 1:194-7.
    View in: PubMed
    Score: 0.038
  16. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006 Feb 15; 107(4):1332-41.
    View in: PubMed
    Score: 0.035
  17. Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther. 2004 Dec; 15(12):1229-42.
    View in: PubMed
    Score: 0.032
  18. Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann N Y Acad Sci. 2003 May; 996:80-8.
    View in: PubMed
    Score: 0.029
  19. Gene transfer and the treatment of haematological malignancy. J Intern Med. 2001 Apr; 249(4):345-58.
    View in: PubMed
    Score: 0.025
  20. Graft-versus-host reactions and bone-marrow transplantation. Curr Opin Immunol. 1991 Oct; 3(5):752-7.
    View in: PubMed
    Score: 0.013
  21. Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus. Blood. 1990 Sep 01; 76(5):1046-53.
    View in: PubMed
    Score: 0.012
  22. Allogeneic bone marrow transplantation. Recent developments and the potential expansion of the donor pool. Acta Oncol. 1988; 27(5):567-70.
    View in: PubMed
    Score: 0.010
  23. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet. 1986 Feb 15; 1(8477):339-43.
    View in: PubMed
    Score: 0.009
  24. The use of monoclonal antibodies in graft versus host disease prevention. Haematologia (Budap). 1986; 19(3):167-76.
    View in: PubMed
    Score: 0.009
  25. Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann Hematol. 2002; 81 Suppl 2:S42-3.
    View in: PubMed
    Score: 0.007
  26. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5.
    View in: PubMed
    Score: 0.004
  27. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
    View in: PubMed
    Score: 0.004
  28. T cell depleted bone marrow transplantation in acute myeloblastic leukaemia: the way ahead. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:225-8.
    View in: PubMed
    Score: 0.003
  29. Immunofluorescent studies of human leukemic cells with antiserum to a murine leukemic virus (Rauscher strain). Blood. 1968 Mar; 31(3):381-7.
    View in: PubMed
    Score: 0.003
  30. CD5-positive B cells after T cell depleted bone marrow transplantation. Clin Exp Immunol. 1987 Jun; 68(3):662-8.
    View in: PubMed
    Score: 0.002
  31. Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol. 1986 Mar; 62(3):413-20.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.